Literature DB >> 15700028

Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor-independent mechanism.

Angelo Vaccani1, Paola Massi, Arianna Colombo, Tiziana Rubino, Daniela Parolaro.   

Abstract

We evaluated the ability of cannabidiol (CBD) to impair the migration of tumor cells stimulated by conditioned medium. CBD caused concentration-dependent inhibition of the migration of U87 glioma cells, quantified in a Boyden chamber. Since these cells express both cannabinoid CB1 and CB2 receptors in the membrane, we also evaluated their engagement in the antimigratory effect of CBD. The inhibition of cell was not antagonized either by the selective cannabinoid receptor antagonists SR141716 (CB1) and SR144528 (CB2) or by pretreatment with pertussis toxin, indicating no involvement of classical cannabinoid receptors and/or receptors coupled to Gi/o proteins. These results reinforce the evidence of antitumoral properties of CBD, demonstrating its ability to limit tumor invasion, although the mechanism of its pharmacological effects remains to be clarified.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15700028      PMCID: PMC1576089          DOI: 10.1038/sj.bjp.0706134

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  17 in total

Review 1.  Endocannabinoids in the immune system and cancer.

Authors:  Daniela Parolaro; P Massi; T Rubino; E Monti
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2002 Feb-Mar       Impact factor: 4.006

2.  Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors.

Authors:  Z Járai; J A Wagner; K Varga; K D Lake; D R Compton; B R Martin; A M Zimmer; T I Bonner; N E Buckley; E Mezey; R K Razdan; A Zimmer; G Kunos
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-23       Impact factor: 11.205

Review 3.  International Union of Pharmacology. XXVII. Classification of cannabinoid receptors.

Authors:  A C Howlett; F Barth; T I Bonner; G Cabral; P Casellas; W A Devane; C C Felder; M Herkenham; K Mackie; B R Martin; R Mechoulam; R G Pertwee
Journal:  Pharmacol Rev       Date:  2002-06       Impact factor: 25.468

4.  Differential expression of the CB2 cannabinoid receptor by rodent macrophages and macrophage-like cells in relation to cell activation.

Authors:  S J Carlisle; F Marciano-Cabral; A Staab; C Ludwick; G A Cabral
Journal:  Int Immunopharmacol       Date:  2002-01       Impact factor: 4.932

5.  Hematopoietic cells expressing the peripheral cannabinoid receptor migrate in response to the endocannabinoid 2-arachidonoylglycerol.

Authors:  Meritxell Alberich Jordà; Sandra E Verbakel; Peter J M Valk; Yolanda V Vankan-Berkhoudt; Mauro Maccarrone; Allessandro Finazzi-Agrò; Bob Löwenberg; Ruud Delwel
Journal:  Blood       Date:  2002-04-15       Impact factor: 22.113

6.  2-arachidonoylglycerol induces the migration of HL-60 cells differentiated into macrophage-like cells and human peripheral blood monocytes through the cannabinoid CB2 receptor-dependent mechanism.

Authors:  Seishi Kishimoto; Maiko Gokoh; Saori Oka; Mayumi Muramatsu; Takashi Kajiwara; Keizo Waku; Takayuki Sugiura
Journal:  J Biol Chem       Date:  2003-04-23       Impact factor: 5.157

7.  Nonpsychotropic cannabinoid receptors regulate microglial cell migration.

Authors:  Lisa Walter; Allyn Franklin; Anke Witting; Christian Wade; Yiheng Xie; George Kunos; Ken Mackie; Nephi Stella
Journal:  J Neurosci       Date:  2003-02-15       Impact factor: 6.167

8.  Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide.

Authors:  T Bisogno; L Hanus; L De Petrocellis; S Tchilibon; D E Ponde; I Brandi; A S Moriello; J B Davis; R Mechoulam; V Di Marzo
Journal:  Br J Pharmacol       Date:  2001-10       Impact factor: 8.739

Review 9.  Cannabinoid receptors and their ligands.

Authors:  R G Pertwee; R A Ross
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2002 Feb-Mar       Impact factor: 4.006

Review 10.  Effects of delta-9-tetrahydrocannabinol on human immune function and host defense.

Authors:  Michael D Roth; Gayle C Baldwin; Donald P Tashkin
Journal:  Chem Phys Lipids       Date:  2002-12-31       Impact factor: 3.329

View more
  52 in total

1.  Non-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: pro-apoptotic effects and underlying mechanisms.

Authors:  Luciano De Petrocellis; Alessia Ligresti; Aniello Schiano Moriello; Mariagrazia Iappelli; Roberta Verde; Colin G Stott; Luigia Cristino; Pierangelo Orlando; Vincenzo Di Marzo
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

2.  The orphan receptor GPR55 is a novel cannabinoid receptor.

Authors:  E Ryberg; N Larsson; S Sjögren; S Hjorth; N-O Hermansson; J Leonova; T Elebring; K Nilsson; T Drmota; P J Greasley
Journal:  Br J Pharmacol       Date:  2007-09-17       Impact factor: 8.739

Review 3.  GPR18 in microglia: implications for the CNS and endocannabinoid system signalling.

Authors:  D McHugh
Journal:  Br J Pharmacol       Date:  2012-12       Impact factor: 8.739

4.  Cannabidiol inhibits angiogenesis by multiple mechanisms.

Authors:  M Solinas; P Massi; A R Cantelmo; M G Cattaneo; R Cammarota; D Bartolini; V Cinquina; M Valenti; L M Vicentini; D M Noonan; A Albini; D Parolaro
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

5.  Cannabidiol attenuates cisplatin-induced nephrotoxicity by decreasing oxidative/nitrosative stress, inflammation, and cell death.

Authors:  Hao Pan; Partha Mukhopadhyay; Mohanraj Rajesh; Vivek Patel; Bani Mukhopadhyay; Bin Gao; György Haskó; Pál Pacher
Journal:  J Pharmacol Exp Ther       Date:  2008-12-12       Impact factor: 4.030

Review 6.  The Antitumor Activity of Plant-Derived Non-Psychoactive Cannabinoids.

Authors:  Sean D McAllister; Liliana Soroceanu; Pierre-Yves Desprez
Journal:  J Neuroimmune Pharmacol       Date:  2015-04-28       Impact factor: 4.147

7.  Cannabinoids as anticancer therapeutic agents.

Authors:  Olga Kovalchuk; Igor Kovalchuk
Journal:  Cell Cycle       Date:  2020-04-05       Impact factor: 4.534

8.  N-arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptor.

Authors:  Douglas McHugh; Sherry S J Hu; Neta Rimmerman; Ana Juknat; Zvi Vogel; J Michael Walker; Heather B Bradshaw
Journal:  BMC Neurosci       Date:  2010-03-26       Impact factor: 3.288

9.  Cannabidiolic acid, a major cannabinoid in fiber-type cannabis, is an inhibitor of MDA-MB-231 breast cancer cell migration.

Authors:  Shuso Takeda; Shunsuke Okajima; Hiroko Miyoshi; Kazutaka Yoshida; Yoshiko Okamoto; Tomoko Okada; Toshiaki Amamoto; Kazuhito Watanabe; Curtis J Omiecinski; Hironori Aramaki
Journal:  Toxicol Lett       Date:  2012-09-08       Impact factor: 4.372

10.  Quantitative Analyses of Synergistic Responses between Cannabidiol and DNA-Damaging Agents on the Proliferation and Viability of Glioblastoma and Neural Progenitor Cells in Culture.

Authors:  Liting Deng; Lindsay Ng; Tatsuya Ozawa; Nephi Stella
Journal:  J Pharmacol Exp Ther       Date:  2016-11-07       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.